Home › Filings & Releases › May 2026
Filings & Releases — May 2026
991 documents from 252 companies (264 releases) · updated Nov 7, 2026
No documents match these filters.
Sunday, May 313
- SMMTSummit TherapeuticsReleaseIvonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
- REPLReplimune GroupReleaseReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- IMTXImmaticsReleaseImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Saturday, May 305
- SMMTSummit TherapeuticsReleaseEncouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
- REPLReplimune GroupReleaseReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- IMTXImmaticsReleaseImmatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
- EXELExelixisReleaseExelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026via aggregator
- COGTCogent BiosciencesReleaseCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clini
Friday, May 2922
- VSTMVerastemS-8Employee plan registration
- SYRESpyre Therapeutics8-KCurrent report: officer / director change, shareholder vote
- SCYXScynexis8-KCurrent report: charter / bylaws / fiscal year
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
- RYTMRhythm PharmaceuticalsDEFA14AProxy soliciting material
- REPLReplimune GroupReleaseReplimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
- REPLReplimune Group8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- PMNProMIS NeurosciencesS-8Employee plan registration
- OTLKOutlook Therapeutics8-KCurrent report: other events
- OTLKOutlook Therapeutics424B5Prospectus supplement (offering)
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- JBIOJade BiosciencesReleaseMAY 29, 2026 Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class
- INABIN8bioSCHEDULE 13D/A13D amendment
- IMUXImmunicDEF 14AProxy statement
- IMMXImmix Biopharma8-KCurrent report: shareholder vote
- HURATuHURA Biosciences8-KCurrent report: debt / obligation
- EXELExelixis8-KCurrent report: officer / director change, shareholder vote
- ELOXEloxx PharmaceuticalsSCHEDULE 13G/A13G amendment
- CLYMClimb BioS-3Shelf registration
- CLRBCellectar BiosciencesS-1/ARegistration statement (amended)
- CLRBCellectar BiosciencesCORRESPCORRESP
- CINGCingulateDEFA14AProxy soliciting material
- CINGCingulateDEF 14AProxy statement
- CINGCingulateARSAnnual report to shareholders
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARVNArvinasReleaseArvinas to Present at Jefferies Global Healthcare Conference
- ANABAnaptysBio8-KCurrent report: Reg FD disclosure
- ACHVAchieve Life SciencesPRE 14APRE 14A
Thursday, May 2838
- VRDNViridian Therapeutics8-KCurrent report: agreement terminated
- VORVor BiopharmaReleaseVor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
- VIRVir Biotechnology8-KCurrent report: officer / director change, shareholder vote
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 28, 2026
- TARAProtara Therapeutics424B5Prospectus supplement (offering)
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
- RNTXRein TherapeuticsPRE 14APRE 14A
- RLMDRelmada Therapeutics8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- RCKTRocket PharmaceuticalsSC TO-I/ASC TO-I/A
- RCKTRocket PharmaceuticalsReleaseRocket Pharmaceuticals to Participate in Upcoming Investor Conferences
- QTTBQ32 BioSCHEDULE 13D/A13D amendment
- PTNPalatin TechnologiesCERTCERT
- PTNPalatin Technologies8-A12B8-A12B
- PTNPalatin Technologies25Delisting notice
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- OTLKOutlook Therapeutics8-KCurrent report: other events
- ORKAOruka TherapeuticsReleaseOruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- NRXPNRX PharmaceuticalsReleaseEMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first
- MDNAFMedicenna TherapeuticsReleaseMedicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- KPRXKiora Pharmaceuticals424B3Prospectus (resale / update)
- KODKodiak SciencesReleaseKodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
- IONSIonis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- IMUXImmunic8-KCurrent report: Reg FD disclosure · EX-99.1
- ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- COGTCogent BiosciencesReleaseCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
- CNTBConnect BiopharmaCORRESPCORRESP
- CMPSCOMPASS PathwaysReleaseCompass Pathways Elects Kathleen Tregoning to Board of Directors
- CMPSCOMPASS Pathways8-KCurrent report: shareholder vote
- CLRBCellectar BiosciencesDEFA14AProxy soliciting material
- CLRBCellectar BiosciencesDEF 14AProxy statement
- CHRSCoherus OncologyDEFA14AProxy soliciting material
- CGONCG OncologyReleaseCG Oncology to Present at Upcoming Investor Conferences in June
- ATAIAtai BeckleyReleaseAtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizationscompany site may be offline after the acquisition
- ARTVArtiva BiotherapeuticsSCHEDULE 13D/A13D amendment
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- APGEApogee TherapeuticsReleaseApogee Therapeutics to Participate in Upcoming June Conferencescompany site may be offline after the acquisition
- ALTAltimmuneReleasePemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Announces Planned CEO Succession
- ALLOAllogene TherapeuticsDEFA14AProxy soliciting material
- ALLOAllogene Therapeutics8-KCurrent report: officer / director change
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Wednesday, May 2730
- ZNTLZentalis PharmaceuticalsDEFA14AProxy soliciting material
- ZNTLZentalis Pharmaceuticals8-KCurrent report: officer / director change
- VRDNViridian TherapeuticsReleaseViridian Therapeutics to Participate in Upcoming June Investor Conferences
- TVTXTravere TherapeuticsReleaseTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
- TTRXTurn TherapeuticsReleaseTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
- TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MAY 27, 2026
- TGTXTg Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- SPRBSpruce BiosciencesReleaseSpruce Biosciences to Participate in Upcoming Conferences in June
- SGMTSagimet BiosciencesReleaseSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
- SANASana BiotechnologyReleaseSana Biotechnology to Present at June 2026 Investor Conferences
- QTTBQ32 Bio8-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1
- PALIPalisade BioSCHEDULE 13GPassive >5% holder (13G)
- OKUROnKure TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- NRXPNRX PharmaceuticalsReleaseDeployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and
- KZIAKazia TherapeuticsSCHEDULE 13G/A13G amendment
- KYMRKymera TherapeuticsReleaseWATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
- IMUXImmunic8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- IMCRImmunocore8-KCurrent report: shareholder vote
- GERNGeron8-KCurrent report: officer / director change, shareholder vote
- DTILPrecision Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- CRBUCaribou BiosciencesReleaseCaribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
- CATXPerspective Therapeutics8-KCurrent report: shareholder vote
- ATAIAtai BeckleyReleaseAtaiBeckley to Participate in Upcoming Investor Conferences in June 2026company site may be offline after the acquisition
- APVOAptevo Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
- APGEApogee TherapeuticsReleaseApogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitiscompany site may be offline after the acquisition; linked to the SEC copy · original
- APGEApogee TherapeuticsReleaseApogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibartcompany site may be offline after the acquisition; linked to the SEC copy · original
- APGEApogee Therapeutics8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- APGEApogee Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- ANNXAnnexonReleaseAnnexon to Participate in Upcoming June Investor Conferences
- ALTAltimmuneReleaseNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
- ALTAltimmuneReleaseAltimmune to Participate in Upcoming Investor Conferences
- AKTSAktis OncologyReleaseAKTIS ONCOLOGY TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- AGMBAgomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
Tuesday, May 2638
- VSTMVerastem8-KCurrent report: shareholder vote
- VRDNViridian Therapeutics8-KCurrent report: material agreement
- VKTXViking Therapeutics8-KCurrent report: shareholder vote
- VERAVera Therapeutics8-KCurrent report: shareholder vote
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics to Participate in Upcoming June Investor Conferences
- SPRBSpruce Biosciences8-KCurrent report: shareholder vote
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
- RNACCartesian Therapeutics8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1
- RCUSArcus BiosciencesReleaseArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthc...
- OTLKOutlook TherapeuticsReleaseOutlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
- OTLKOutlook Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- OLMAOlema Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- NGENNervGen PharmaSUPPLSUPPL
- NGENNervGen PharmaReleaseNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
- NGENNervGen PharmaF-XF-X
- NGENNervGen PharmaF-10F-10
- NGENNervGen PharmaEFFECTRegistration effective
- NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MAY 26, 2026
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KZIAKazia Therapeutics424B3Prospectus (resale / update)
- KURAKura OncologyReleaseKura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
- KURAKura OncologyDEFA14AProxy soliciting material
- KAPAKairos PharmaDEFA14AProxy soliciting material
- JBIOJade BiosciencesReleaseMAY 26, 2026 Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
- JBIOJade BiosciencesReleaseMAY 26, 2026 Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
- GPCRStructure TherapeuticsReleaseStructure Therapeutics Announces Participation in Upcoming Investor Conferences
- GANXGain TherapeuticsReleaseGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
- GANXGain Therapeutics8-KCurrent report: other events
- DYNDyne TherapeuticsReleaseDyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
- DTILPrecision Biosciences8-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CMPSCOMPASS PathwaysReleaseCompass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
- CLYMClimb BioReleaseClimb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
- CGONCG Oncology8-KCurrent report: officer / director change
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
- ARDXArdelyxDEFA14AProxy soliciting material
- APGEApogee TherapeuticsReleaseApogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026company site may be offline after the acquisition
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Announces Participation in Upcoming Investor Conferences
Friday, May 2222
- ZURAZura BioDEFA14AProxy soliciting material
- ZURAZura Bio8-KCurrent report: officer / director change
- TARAProtara TherapeuticsEFFECTRegistration effective
- SCYXScynexis8-KCurrent report: shareholder vote, other events
- OTLKOutlook TherapeuticsPRE 14APRE 14A
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- NRXPNRX Pharmaceuticals25-NSEDelisting notice
- NGENNervGen PharmaSUPPLSUPPL
- NGENNervGen PharmaReleaseNervGen Announces Pricing of US$60.0 Million Public Offering of Securities
- NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- MLYSMineralys Therapeutics8-KCurrent report: shareholder vote
- MISTMilestone PharmaceuticalsEFFECTRegistration effective
- MDNAFMedicenna TherapeuticsReleaseMedicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- MAZEMaze Therapeutics8-KCurrent report: officer / director change
- MAIAMAIA Biotechnology8-KCurrent report: shareholder vote
- KPRXKiora PharmaceuticalsEFFECTRegistration effective
- KAPAKairos PharmaDEF 14AProxy statement
- KAPAKairos PharmaARSAnnual report to shareholders
- IBRXImmunityBioReleaseImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
- IBRXImmunityBioReleaseImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
- GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
- CRNXCrinetics PharmaceuticalsReleaseCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026company site may be offline after the acquisition
- CNTBConnect BiopharmaUPLOADUPLOAD
- CLRBCellectar BiosciencesUPLOADUPLOAD
- CLNNCleneSDSpecialized disclosure
- CLNNClene8-KCurrent report: material agreement, officer / director change, shareholder vote
- CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1
- ACTUActuate Therapeutics8-KCurrent report: shareholder vote
- ACRVAcrivon TherapeuticsDEFA14AProxy soliciting material
- ABVXAbivax6-KForeign issuer report · EX-99.1
Thursday, May 2132
- ZNTLZentalis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- TVTXTravere Therapeutics8-KCurrent report: officer / director change, shareholder vote · EX-99.1
- TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 21, 2026
- SANASana BiotechnologySCHEDULE 13GPassive >5% holder (13G)
- RLAYRelay Therapeutics8-KCurrent report: material agreement
- RLAYRelay Therapeutics424B5Prospectus supplement (offering)
- REPLReplimune GroupSCHEDULE 13GPassive >5% holder (13G)
- RCKTRocket Pharmaceuticals8-KCurrent report: shareholder vote
- PEPGPepGenEFFECTRegistration effective
- PEPGPepGen8-KCurrent report: Reg FD disclosure · EX-99.1
- PALIPalisade BioEFFECTRegistration effective
- OLMAOlema Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- NGENNervGen PharmaSUPPLSUPPL
- NGENNervGen PharmaReleaseNervGen Announces Proposed Public Offering of Securities
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
- IPSCCentury Therapeutics424B7Prospectus supplement
- IMRXImmuneeringReleaseImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
- IMMXImmix BiopharmaFWPFree writing prospectus (offering terms)
- IMMXImmix Biopharma8-KCurrent report: other events · EX-99.1
- IMMXImmix Biopharma8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- IMMXImmix Biopharma424B5Prospectus supplement (offering)
- GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- CUECue BiopharmaDEF 14AProxy statement
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics to Present at Upcoming June Investor Conferences
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- CGTXCognition Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- CGENCompugenUPLOADUPLOAD
- CBIOCrescent BiopharmaReleaseCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- CATXPerspective TherapeuticsReleasePerspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
- BDTXBlack Diamond Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- BCYCBicycle Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- BCAXBicara Therapeutics8-KCurrent report: other events · EX-99.1
- ANABAnaptysBio8-KCurrent report: charter / bylaws / fiscal year
- ALLOAllogene TherapeuticsDEFA14AProxy soliciting material
- AKTSAktis OncologyReleaseAKTIS ONCOLOGY REPORTS FIRST-IN-HUMAN CLINICAL IMAGING AND DOSIMETRY DATA FOR AKY-2519 DEMONSTRATING ROBUST TUMOR UPTAKE AND LIMITED NORMAL TISSUE EXPOSURES IN PATIENTS WITH B7-H3 EXPRESSING TUMORS
- ACRVAcrivon TherapeuticsReleaseAcrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
- ACHVAchieve Life SciencesEFFECTRegistration effective
Wednesday, May 2015
- TENXTenax TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TARAProtara TherapeuticsReleaseProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
- TARAProtara TherapeuticsCORRESPCORRESP
- PMNProMIS Neurosciences8-KCurrent report: officer / director change, shareholder vote
- MISTMilestone PharmaceuticalsCORRESPCORRESP
- LGVNLongeveronDEFA14AProxy soliciting material
- LGVNLongeveronDEF 14AProxy statement
- LGVNLongeveronARSAnnual report to shareholders
- KPRXKiora PharmaceuticalsUPLOADUPLOAD
- KPRXKiora PharmaceuticalsCORRESPCORRESP
- IRDOpus GeneticsSCHEDULE 13D/A13D amendment
- IMVTImmunovant8-KCurrent report: results of operations · EX-99.1
- IMVTImmunovant10-KAnnual report
- IBRXImmunityBioReleaseImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
- DYNDyne TherapeuticsReleaseDyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
- CYDYCytoDynEFFECTRegistration effective
- CYDYCytoDyn424B3Prospectus (resale / update)
- CCCCC4 TherapeuticsReleaseC4 Therapeutics to Participate in Upcoming Conferences
- BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ACETAdicet Bio10-K/AAnnual report (amended)
- ABVXAbivax6-KForeign issuer report · EX-99.1
- ABSIAbsciReleaseAbsci to Participate in Upcoming Investor Conferences
Tuesday, May 1928
- TTRXTurn TherapeuticsReleaseTurn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
- TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MAY 19, 2026
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 19, 2026
- TARAProtara TherapeuticsUPLOADUPLOAD
- RLAYRelay Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- RLAYRelay Therapeutics424B5Prospectus supplement (offering)
- PEPGPepGenCORRESPCORRESP
- PALIPalisade BioUPLOADUPLOAD
- PALIPalisade BioCORRESPCORRESP
- NKTXNkartaSCHEDULE 13D/A13D amendment
- MDNAFMedicenna TherapeuticsReleaseMedicenna Announces the Finalization of the Terms of its Public Offering of Securities
- MAIAMAIA BiotechnologyDEFA14AProxy soliciting material
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conferencecompany site may be offline after the acquisition
- LRMRLarimar Therapeutics8-KCurrent report: shareholder vote
- IVVDInvivyd8-KCurrent report: shareholder vote
- INABIN8bioEFFECTRegistration effective
- IMUXImmunic8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- IBRXImmunityBioReleaseImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
- GHRSGH ResearchEFFECTRegistration effective
- FBIOFortress BiotechReleaseJourney Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
- EYPTEyePointReleaseEyePoint Announces Participation at Upcoming Investor Conferences
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
- ETONEton Pharmaceuticals8-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO HEMANGEOL LICENSING AGREEEMENT
- DFTXDefinium Therapeutics8-KCurrent report: other events · EX-99.1
- CLRBCellectar BiosciencesS-1Registration statement
- CINGCingulate8-KCurrent report: officer / director change
- CGONCG OncologyReleaseSUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
- CCCCC4 TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ATHEAlterity TherapeuticsReleaseAlterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cel
- ARTVArtiva Biotherapeutics8-KCurrent report: officer / director change
- ARDXArdelyxDEFA14AProxy soliciting material
- ACHVAchieve Life SciencesCORRESPCORRESP
Monday, May 1840
- WVEWave Life SciencesReleaseWave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
- WVEWave Life Sciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- VIRVir BiotechnologyRelease(Opens PDF Titled Vir Biotechnology Announces First Patient Dosed In Phase 1 Dose-Expansion Cohorts Evaluating PSMA-Targeted, PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 In Patients With Metastatic
- VIRVir BiotechnologyReleaseVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
- TTRXTurn TherapeuticsReleaseTurn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
- TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MAY 18, 2026
- TARAProtara TherapeuticsReleaseProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- RVPHReviva PharmaceuticalsReleaseOTCQB: RVPH
- RAREUltragenyx Pharmaceutical8-KCurrent report: officer / director change, shareholder vote
- PTNPalatin Technologies8-KCurrent report: listing notice, Reg FD disclosure · EX-99.1
- PEPGPepGenS-3Shelf registration
- OTLKOutlook Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- NRXPNRX PharmaceuticalsReleaseKey highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026,
- NGENNervGen PharmaReleaseNervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
- NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- MISTMilestone PharmaceuticalsUPLOADUPLOAD
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Names Greg Martini as Chief Financial Officer
- KYTXKyverna Therapeutics8-KCurrent report: officer / director change, other events · EX-99.1
- KPRXKiora PharmaceuticalsS-3Shelf registration
- KAPAKairos Pharma8-KCurrent report: other events · EX-99.1
- INABIN8bioS-3/AShelf registration (amended)
- IBRXImmunityBioReleaseImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
- IBRXImmunityBio8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- GOSSGossamer BioReleaseGossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
- GOSSGossamer BioReleaseGossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
- GOSSGossamer BioPRE 14APRE 14A
- GOSSGossamer BioDEFA14AProxy soliciting material
- GOSSGossamer Bio8-KCurrent report: material agreement, results of operations, officer / director change · EX-99.1
- GHRSGH ResearchSCHEDULE 13G/A13G amendment
- FBIOFortress BiotechReleaseFortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 NOTICE AND PROXY STATEMENT FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF THE
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MAY 18, 2026
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
- CRVOCervoMedReleaseCervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- CRVOCervoMed8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- CLRBCellectar BiosciencesPRE 14APRE 14A
- CLRBCellectar Biosciences8-KCurrent report: officer / director change
- CINGCingulatePRE 14APRE 14A
- CGENCompugenF-3Shelf registration (foreign)
- CGENCompugen6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
- CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- CATXPerspective TherapeuticsReleasePerspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
- BEAMBeam TherapeuticsReleaseBeam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
- ARVNArvinasReleaseArvinas Employees Give Back During Company-wide Impact Day
- ARTVArtiva BiotherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ACHVAchieve Life SciencesUPLOADUPLOAD
Saturday, May 161
Friday, May 1534
- ZYMEZymeworksSCHEDULE 13G/A13G amendment
- ZURAZura BioSCHEDULE 13G/A13G amendment
- ZURAZura BioSCHEDULE 13G/A13G amendment
- XNCRXencorSCHEDULE 13G/A13G amendment
- XFORX4 PharmaceuticalsSCHEDULE 13G/A13G amendment
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- VYGRVoyager TherapeuticsSCHEDULE 13G/A13G amendment
- VYGRVoyager TherapeuticsSCHEDULE 13G/A13G amendment
- VSTMVerastemSCHEDULE 13G/A13G amendment
- VSTMVerastemSCHEDULE 13G/A13G amendment
- VSTMVerastemSCHEDULE 13G/A13G amendment
- VSTMVerastemSCHEDULE 13G/A13G amendment
- VRDNViridian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VIRVir BiotechnologySCHEDULE 13G/A13G amendment
- VERAVera TherapeuticsSCHEDULE 13G/A13G amendment
- UNCYUnicycive TherapeuticsSCHEDULE 13G/A13G amendment
- TYRATyra BiosciencesSCHEDULE 13G/A13G amendment
- TYRATyra BiosciencesSCHEDULE 13G/A13G amendment
- TVTXTravere TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TSHATaysha Gene TherapiesSCHEDULE 13G/A13G amendment
- TSHATaysha Gene TherapiesSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TARAProtara TherapeuticsSCHEDULE 13G/A13G amendment
- TARAProtara TherapeuticsReleaseProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
- STROSutro BiopharmaSCHEDULE 13G/A13G amendment
- STROSutro BiopharmaSCHEDULE 13GPassive >5% holder (13G)
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SNDXSyndax PharmaceuticalsSCHEDULE 13G/A13G amendment
- SIONSionna TherapeuticsSCHEDULE 13G/A13G amendment
- SCYXScynexisSCHEDULE 13G/A13G amendment
- SANASana BiotechnologyReleaseSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
- SANASana Biotechnology8-KCurrent report: other events
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- SABSSAB BiotherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RYTMRhythm PharmaceuticalsSCHEDULE 13G/A13G amendment
- RVPHReviva PharmaceuticalsSCHEDULE 13G/A13G amendment
- RVMDRevolution MedicinesSCHEDULE 13G/A13G amendment
- RNTXRein Therapeutics10-QQuarterly report
- RLAYRelay TherapeuticsSCHEDULE 13G/A13G amendment
- REPLReplimune GroupSCHEDULE 13G/A13G amendment
- RAPPRapport TherapeuticsSCHEDULE 13G/A13G amendment
- QUREuniQureSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13GPassive >5% holder (13G)
- QNRXQuoin PharmaceuticalsSCHEDULE 13G/A13G amendment
- QNRXQuoin PharmaceuticalsSCHEDULE 13G/A13G amendment
- QNRXQuoin PharmaceuticalsSCHEDULE 13G/A13G amendment
- PTNPalatin TechnologiesSCHEDULE 13G/A13G amendment
- PTNPalatin TechnologiesSCHEDULE 13G/A13G amendment
- PTNPalatin TechnologiesSCHEDULE 13GPassive >5% holder (13G)
- PMVPPMV PharmaceuticalsSCHEDULE 13G/A13G amendment
- PMNProMIS NeurosciencesSCHEDULE 13GPassive >5% holder (13G)
- PMNProMIS NeurosciencesSCHEDULE 13GPassive >5% holder (13G)
- PEPGPepGenSCHEDULE 13G/A13G amendment
- PEPGPepGenSCHEDULE 13G/A13G amendment
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- PCSAProcessa PharmaceuticalsSCHEDULE 13G/A13G amendment
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- PALIPalisade BioSCHEDULE 13GPassive >5% holder (13G)
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- OVIDOvid TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- OVIDOvid TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- OTLKOutlook Therapeutics10-QQuarterly report
- ORKAOruka TherapeuticsSCHEDULE 13G/A13G amendment
- ORICOric PharmaceuticalsSCHEDULE 13G/A13G amendment
- ORICOric PharmaceuticalsSCHEDULE 13G/A13G amendment
- ORICOric PharmaceuticalsSCHEDULE 13G/A13G amendment
- ORICOric PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- OLMAOlema PharmaceuticalsSCHEDULE 13G/A13G amendment
- OLMAOlema PharmaceuticalsSCHEDULE 13G/A13G amendment
- OKUROnKure TherapeuticsSCHEDULE 13G/A13G amendment
- NRXPNRX PharmaceuticalsSCHEDULE 13G/A13G amendment
- NRXPNRX Pharmaceuticals10-QQuarterly report
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- NRIXNurix Therapeutics8-KCurrent report: shareholder vote
- NKTRNektar TherapeuticsSCHEDULE 13G/A13G amendment
- NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- MRKRMarker Therapeutics10-QQuarterly report
- MPLTMapLight TherapeuticsSCHEDULE 13G/A13G amendment
- MLTXMoonLake ImmunotherapeuticsSCHEDULE 13G/A13G amendment
- MISTMilestone PharmaceuticalsSCHEDULE 13G/A13G amendment
- MBRXMoleculin Biotech8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- MAZEMaze TherapeuticsSCHEDULE 13G/A13G amendment
- MAIAMAIA BiotechnologySCHEDULE 13GPassive >5% holder (13G)
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment
- LGVNLongeveronSCHEDULE 13GPassive >5% holder (13G)
- LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
- LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
- LBRXLB PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- KYMRKymera TherapeuticsSCHEDULE 13G/A13G amendment
- KYMRKymera TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- KYMRKymera TherapeuticsReleaseLate-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases K
- KURAKura OncologySCHEDULE 13G/A13G amendment
- KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
- KTTAPasithea Therapeutics10-QQuarterly report
- KROSKeros TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- KPRXKiora PharmaceuticalsSCHEDULE 13G/A13G amendment
- KPRXKiora PharmaceuticalsSCHEDULE 13G/A13G amendment
- KPRXKiora PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- KODKodiak SciencesSCHEDULE 13GPassive >5% holder (13G)
- JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
- JBIOJade BiosciencesEFFECTRegistration effective
- JBIOJade BiosciencesEFFECTRegistration effective
- JBIOJade Biosciences424B3Prospectus (resale / update)
- JANXJanux TherapeuticsSCHEDULE 13G/A13G amendment
- IXHLIncannex Healthcare10-QQuarterly report
- IVVDInvivydSCHEDULE 13G/A13G amendment
- IVVDInvivydSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13GPassive >5% holder (13G)
- IPSCCentury TherapeuticsSCHEDULE 13G/A13G amendment
- IPSCCentury TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- IONSIonis PharmaceuticalsSCHEDULE 13G/A13G amendment
- INSMInsmedSCHEDULE 13G/A13G amendment
- INSMInsmedS-3ASRAutomatic shelf registration
- INSMInsmed8-KCurrent report: shareholder vote
- INKTMiNK Therapeutics8-KCurrent report: results of operations · EX-99.1
- INKTMiNK Therapeutics10-QQuarterly report
- INBXInhibrx BiosciencesSCHEDULE 13G/A13G amendment
- INBXInhibrx BiosciencesSCHEDULE 13G/A13G amendment
- INABIN8bioCORRESPCORRESP
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMTXImmaticsSCHEDULE 13G/A13G amendment
- IMTXImmaticsSCHEDULE 13G/A13G amendment
- IMTXImmaticsSCHEDULE 13G/A13G amendment
- IMTXImmaticsSCHEDULE 13GPassive >5% holder (13G)
- IMRXImmuneeringReleaseImmuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- IMRXImmuneering8-KCurrent report: results of operations · EX-99.1
- IMRXImmuneering10-QQuarterly report
- IMNMImmunomeSCHEDULE 13G/A13G amendment
- IMNMImmunomeSCHEDULE 13G/A13G amendment
- IMNMImmunomeSCHEDULE 13G/A13G amendment
- IMNMImmunomeSCHEDULE 13GPassive >5% holder (13G)
- IMMXImmix BiopharmaSCHEDULE 13G/A13G amendment
- IMCRImmunocoreSCHEDULE 13G/A13G amendment
- IMCRImmunocoreSCHEDULE 13GPassive >5% holder (13G)
- IDYAIDEAYA BiosciencesSCHEDULE 13G/A13G amendment
- HURATuHURA Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- HURATuHURA Biosciences10-QQuarterly report
- HELPHelus PharmaSCHEDULE 13G/A13G amendment
- HELPHelus PharmaSCHEDULE 13GPassive >5% holder (13G)
- GUTSFractyl HealthSCHEDULE 13G/A13G amendment
- GUTSFractyl HealthSCHEDULE 13G/A13G amendment
- GRCEGrace TherapeuticsSCHEDULE 13G/A13G amendment
- GOSSGossamer BioReleaseGossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
- GOSSGossamer Bio10-QQuarterly report
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GHRSGH ResearchUPLOADUPLOAD
- GHRSGH ResearchSCHEDULE 13G/A13G amendment
- GHRSGH ResearchCORRESPCORRESP
- GERNGeronSCHEDULE 13G/A13G amendment
- FHTXFoghorn TherapeuticsSCHEDULE 13G/A13G amendment
- FDMT4D Molecular TherapeuticsSCHEDULE 13G/A13G amendment
- FDMT4D Molecular TherapeuticsSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- FBIOFortress BiotechSCHEDULE 13G/A13G amendment
- EYPTEyePointSCHEDULE 13G/A13G amendment
- EWTXEdgewise TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ERASErascaSCHEDULE 13G/A13G amendment
- ERASErascaSCHEDULE 13G/A13G amendment
- ERASErascaSCHEDULE 13G/A13G amendment
- ERASErascaSCHEDULE 13GPassive >5% holder (13G)
- ENTXEntera BioEFFECTRegistration effective
- ENTXEntera Bio424B3Prospectus (resale / update)
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELDNEledon PharmaceuticalsSCHEDULE 13G/A13G amendment
- EIKNEikon TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- DYNDyne TherapeuticsSCHEDULE 13G/A13G amendment
- DYNDyne TherapeuticsSCHEDULE 13G/A13G amendment
- DFTXDefinium TherapeuticsSCHEDULE 13G/A13G amendment
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- CYDYCytoDynReleaseCytoDyn to Present at the LD Micro Invitational XVI
- CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
- CTNMContineum TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
- CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
- CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
- CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
- CTMXCytomX TherapeuticsSCHEDULE 13G/A13G amendment
- CRVSCorvus PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRVSCorvus PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- CRVOCervoMed10-QQuarterly report
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRDLCardiol TherapeuticsSCHEDULE 13G/A13G amendment
- CNTBConnect BiopharmaSCHEDULE 13G/A13G amendment
- CNTBConnect BiopharmaF-3Shelf registration (foreign)
- CMPXCompass TherapeuticsSCHEDULE 13G/A13G amendment
- CMPSCOMPASS PathwaysSCHEDULE 13G/A13G amendment
- CLNNCleneSCHEDULE 13G/A13G amendment
- CLDXCelldex TherapeuticsSCHEDULE 13G/A13G amendment
- CLDXCelldex TherapeuticsSCHEDULE 13G/A13G amendment
- CHRSCoherus OncologySCHEDULE 13G/A13G amendment
- CGONCG OncologySCHEDULE 13GPassive >5% holder (13G)
- CGONCG OncologySCHEDULE 13GPassive >5% holder (13G)
- CGONCG OncologyReleaseCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- CGEMCullinan TherapeuticsSCHEDULE 13G/A13G amendment
- CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
- CCCCC4 TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CCCCC4 Therapeutics8-KCurrent report: officer / director change
- CBIOCrescent BiopharmaSCHEDULE 13G/A13G amendment
- CBIOCrescent BiopharmaSCHEDULE 13GPassive >5% holder (13G)
- CADLCandel TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CADLCandel Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- BIOABioAge LabsSCHEDULE 13G/A13G amendment
- BIOABioAge LabsSCHEDULE 13G/A13G amendment
- BCYCBicycle TherapeuticsSCHEDULE 13G/A13G amendment
- BCYCBicycle TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- BCAXBicara TherapeuticsSCHEDULE 13G/A13G amendment
- BCAXBicara TherapeuticsSCHEDULE 13G/A13G amendment
- BCAXBicara TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- AUTLAutolus TherapeuticsSCHEDULE 13G/A13G amendment
- AUTLAutolus TherapeuticsSCHEDULE 13G/A13G amendment
- ARDXArdelyxSCHEDULE 13G/A13G amendment
- ANTXAN2 TherapeuticsSCHEDULE 13G/A13G amendment
- ANNXAnnexonSCHEDULE 13G/A13G amendment
- ANABAnaptysBioSCHEDULE 13G/A13G amendment
- ANABAnaptysBioSCHEDULE 13GPassive >5% holder (13G)
- AMLXAmylyx PharmaceuticalsSCHEDULE 13G/A13G amendment
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
- ALTAltimmuneSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsSCHEDULE 13G/A13G amendment
- ALDXAldeyra TherapeuticsSCHEDULE 13G/A13G amendment
- AGMBAgomab TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- AGMBAgomab TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- AGIOAgios PharmaceuticalsSCHEDULE 13G/A13G amendment
- ADAGAdageneSCHEDULE 13G/A13G amendment
- ACRVAcrivon TherapeuticsSCHEDULE 13G/A13G amendment
- ACIUAC Immune6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ACETAdicet BioSCHEDULE 13G/A13G amendment
Thursday, May 1480
- ZYMEZymeworks8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- XFORX4 PharmaceuticalsEFFECTRegistration effective
- VORVor BiopharmaReleaseVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
- TYRATyra BiosciencesSCHEDULE 13G/A13G amendment
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 14, 2026
- TARAProtara TherapeuticsS-3Shelf registration
- STROSutro BiopharmaSCHEDULE 13G/A13G amendment
- STROSutro Biopharma8-KCurrent report: results of operations · EX-99.1
- STROSutro Biopharma10-QQuarterly report
- SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences to Participate in Upcoming Investor Conferences
- RVPHReviva PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- ONCYOncolytics Biotech10-QQuarterly report
- OCSOculis Holding6-KForeign issuer report · EX-99.1
- OCGNOcugenReleaseOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
- OCGNOcugen8-KCurrent report: officer / director change, other events
- OCGNOcugen8-KCurrent report: debt / obligation, unregistered sale of equity, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- NRXPNRX PharmaceuticalsReleaseWILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it
- NRIXNurix TherapeuticsReleaseNurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual M
- NAMSNewAmsterdam PharmaSCHEDULE 13D/A13D amendment
- MPLTMapLight Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- MPLTMapLight Therapeutics10-QQuarterly report
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- MGTXMeiraGTx8-KCurrent report: results of operations · EX-99.1
- MGTXMeiraGTx10-QQuarterly report
- MBRXMoleculin Biotech10-QQuarterly report
- MAIAMAIA Biotechnology8-KCurrent report: agreement terminated
- MAIAMAIA Biotechnology424B5Prospectus supplement (offering)
- LRMRLarimar TherapeuticsSCHEDULE 13G/A13G amendment
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Reports First Quarter 2026 Financial and Business Update
- LRMRLarimar Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- LRMRLarimar Therapeutics10-QQuarterly report
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics to Present at Upcoming Investor Conferences
- KROSKeros Therapeutics8-KCurrent report: results of operations · EX-99.1
- KROSKeros Therapeutics10-QQuarterly report
- IXHLIncannex HealthcareReleaseIncannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
- IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MAY 14, 2026
- IVVDInvivydS-8Employee plan registration
- IVVDInvivyd8-KCurrent report: results of operations, other events · EX-99.1
- IVVDInvivyd10-QQuarterly report
- IRDOpus GeneticsS-8Employee plan registration
- IONSIonis PharmaceuticalsSCHEDULE 13G/A13G amendment
- INMBInmune Bio8-KCurrent report: other events · EX-99.1 PRESS RELEASE DATED MAY 14, 2026
- INBXInhibrx Biosciences8-KCurrent report: results of operations · EX-99.1
- INBXInhibrx Biosciences10-QQuarterly report
- HRMYHarmony Biosciences8-KCurrent report: shareholder vote
- GOSSGossamer BioSCHEDULE 13G/A13G amendment
- GHRSGH ResearchReleaseGH Research Reports First Quarter 2026 Financial Results and Provides Business Update May 14, 2026 Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses s
- GHRSGH ResearchF-3Shelf registration (foreign)
- GHRSGH Research6-KForeign issuer report
- GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GHRSGH Research424B5Prospectus supplement (offering)
- FHTXFoghorn TherapeuticsSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte Biosciences8-KCurrent report: results of operations · EX-99.1
- FBIOFortress BiotechReleaseFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- FBIOFortress Biotech8-KCurrent report: results of operations · EX-99
- FBIOFortress Biotech10-QQuarterly report
- EYPTEyePoint8-KCurrent report: other events · EX-99.1
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Reports First Quarter 2026 Financial Results
- ETONEton Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- ETONEton Pharmaceuticals10-QQuarterly report
- ENTXEntera BioPRE 14APRE 14A
- CUECue BiopharmaDForm D (exempt offering)
- CUECue Biopharma8-KCurrent report · EX-99.1
- CUECue Biopharma10-QQuarterly report
- CRVSCorvus Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- CRDLCardiol TherapeuticsReleaseCardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED MAY 14, 2026
- COGTCogent BiosciencesSCHEDULE 13G/A13G amendment
- CMPSCOMPASS PathwaysReleaseCompass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
- CMMBChemomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CLYMClimb BioReleaseClimb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
- CLRBCellectar Biosciences8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- CLRBCellectar Biosciences10-QQuarterly report
- CLNNCleneSCHEDULE 13G/A13G amendment
- CLNNCleneSCHEDULE 13G/A13G amendment
- CLNNCleneReleaseClene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
- CLNNClene8-KCurrent report: material agreement, results of operations · EX-99.1 EXHIBIT 99.1
- CLNNClene10-QQuarterly report
- CINGCingulateRelease2026 2025 ArchiveBD extracted 1 program update from this document → CING pipeline
- CINGCingulateReleaseCingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
- CINGCingulate8-KCurrent report: results of operations · EX-99.1
- CINGCingulate10-QQuarterly report
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
- CADLCandel Therapeutics8-KCurrent report: results of operations · EX-99.1
- CADLCandel Therapeutics10-QQuarterly report
- CABACabaletta BioReleaseCabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
- CABACabaletta BioReleaseCabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
- CABACabaletta Bio8-KCurrent report: results of operations · EX-99.1
- CABACabaletta Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- CABACabaletta Bio10-QQuarterly report
- BLTEBelite BioSCHEDULE 13G/A13G amendment
- AUTLAutolus Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- AUTLAutolus Therapeutics10-QQuarterly report
- AKTSAktis OncologySCHEDULE 13GPassive >5% holder (13G)
- ACTUActuate TherapeuticsS-8Employee plan registration
- ACTUActuate Therapeutics10-QQuarterly report
- AARDAardvark Therapeutics8-KCurrent report: other events · EX-99.1
Wednesday, May 1386
- ZBIOZenas BioPharma8-KCurrent report: results of operations, officer / director change, shareholder vote · EX-99.1 EXHIBIT 99.1
- ZBIOZenas BioPharma10-QQuarterly report
- XFORX4 Pharmaceuticals8-K/ACurrent report (amended): officer / director change, shareholder vote
- WVEWave Life SciencesSCHEDULE 13G/A13G amendment
- WVEWave Life SciencesReleaseWave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
- VYGRVoyager TherapeuticsReleaseVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
- VTVTvTv TherapeuticsS-8Employee plan registration
- VTVTvTv TherapeuticsReleasevTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- VTVTvTv Therapeutics8-KCurrent report: results of operations · EX-99.1
- VTVTvTv Therapeutics8-KCurrent report: other events
- VTVTvTv Therapeutics424B2Prospectus supplement
- VTVTvTv Therapeutics10-QQuarterly report
- VRDNViridian TherapeuticsSCHEDULE 13D/A13D amendment
- VORVor BiopharmaReleaseVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
- VORVor Biopharma10-QQuarterly report
- TYRATyra Biosciences8-KCurrent report: results of operations · EX-99.1
- TYRATyra Biosciences10-QQuarterly report
- TTRXTurn TherapeuticsC-TRC-TR
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsReleaseTango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
- TNGXTango Therapeutics8-KCurrent report: results of operations, officer / director change · EX-99.1
- TNGXTango Therapeutics10-QQuarterly report
- TARAProtara TherapeuticsReleaseProtara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
- TARAProtara Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED MAY 13, 2026, ISSUED BY THE REGISTRANT
- TARAProtara Therapeutics10-QQuarterly report
- SRPTSarepta TherapeuticsReleaseSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
- SRPTSarepta Therapeutics13F-HR13F-HR
- SPRBSpruce BiosciencesS-8Employee plan registration
- SPRBSpruce Biosciences8-KCurrent report: results of operations · EX-99.1
- SPRBSpruce Biosciences10-QQuarterly report
- SGMTSagimet BiosciencesReleaseSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- RVPHReviva Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- RVPHReviva Pharmaceuticals8-KCurrent report: listing notice, other events
- RVPHReviva Pharmaceuticals10-QQuarterly report
- RLMDRelmada TherapeuticsSCHEDULE 13G/A13G amendment
- RLMDRelmada TherapeuticsS-3ASRAutomatic shelf registration
- PYPDPolyPid6-KForeign issuer report · EX-99.1 PRESS RELEASE ISSUED BY POLYPID LTD. ON MAY 13, 2026, TITLED "POLYPID PROVIDES C
- PTNPalatin Technologies10-QQuarterly report
- OTLKOutlook Therapeutics8-KCurrent report: material agreement, agreement terminated, results of operations
- OTLKOutlook Therapeutics424B5Prospectus supplement (offering)
- ORKAOruka Therapeutics10-QQuarterly report
- OMEROmerosReleaseOmeros Corporation Reports First Quarter 2026 Financial Results
- OMEROmeros8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- OMEROmeros10-QQuarterly report
- OCGNOcugenReleaseOcugen to Participate in Upcoming May Scientific and Investor Conferences
- NRIXNurix TherapeuticsReleaseNurix Therapeutics to Participate in Upcoming Investor Conferences
- MISTMilestone PharmaceuticalsSCHEDULE 13G/A13G amendment
- MISTMilestone PharmaceuticalsS-3Shelf registration
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
- MISTMilestone Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- MISTMilestone Pharmaceuticals10-QQuarterly report
- MGTXMeiraGTxSCHEDULE 13G/A13G amendment
- MDNAFMedicenna TherapeuticsReleaseMedicenna Announces the Launch of a Marketed Public Offering of Securities
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- MAZEMaze TherapeuticsEFFECTRegistration effective
- LGVNLongeveron8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON MAY 13, 2026
- LGVNLongeveron10-QQuarterly report
- LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
- KAPAKairos Pharma10-QQuarterly report
- JBIOJade BiosciencesUPLOADUPLOAD
- JBIOJade BiosciencesUPLOADUPLOAD
- JBIOJade BiosciencesCORRESPCORRESP
- JBIOJade BiosciencesCORRESPCORRESP
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13GPassive >5% holder (13G)
- IPSCCentury TherapeuticsReleaseCentury Therapeutics Reports First Quarter Financial Results and Business Updates
- IPSCCentury Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- IPSCCentury Therapeutics10-QQuarterly report
- IMUXImmunic8-KCurrent report: results of operations · EX-99.1
- IMUXImmunic10-QQuarterly report
- GUTSFractyl HealthSCHEDULE 13G/A13G amendment
- GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GHRSGH Research6-KForeign issuer report
- FDMT4D Molecular TherapeuticsEFFECTRegistration effective
- FBRXForte BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- FBIOFortress BiotechReleaseJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- FATEFate Therapeutics8-KCurrent report: results of operations · EX-99.1
- FATEFate Therapeutics10-QQuarterly report
- EYPTEyePointSCHEDULE 13G/A13G amendment
- ENTXEntera BioCORRESPCORRESP
- ENTAEnanta PharmaceuticalsS-8Employee plan registration
- ENTAEnanta Pharmaceuticals10-QQuarterly report
- ELDNEledon Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- ELDNEledon Pharmaceuticals10-QQuarterly report
- EIKNEikon TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- DYNDyne TherapeuticsReleaseDyne Therapeutics to Participate in Upcoming Investor Conferences
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- CRBUCaribou BiosciencesReleaseCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
- COYACoya TherapeuticsDEFA14AProxy soliciting material
- COYACoya TherapeuticsDEF 14AProxy statement
- COYACoya TherapeuticsARSAnnual report to shareholders
- CMPSCOMPASS PathwaysReleaseCompass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
- CMPSCOMPASS Pathways8-KCurrent report: results of operations · EX-99.1
- CMPSCOMPASS Pathways10-QQuarterly report
- CAPRCapricor Therapeutics10-QQuarterly report
- BEAMBeam TherapeuticsReleaseBeam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
- BBOTBridgeBio Oncology Therapeutics424B3Prospectus (resale / update)
- ARTVArtiva BiotherapeuticsSCHEDULE 13D/A13D amendment
- APVOAptevo Therapeutics8-KCurrent report: results of operations · EX-99.1
- APVOAptevo Therapeutics10-QQuarterly report
- ALTAltimmuneS-8Employee plan registration
- ALTAltimmuneReleaseAltimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
- ALTAltimmuneReleaseAltimmune Announces First Quarter 2026 Financial Results and Business Update
- ALTAltimmune8-KCurrent report: results of operations · EX-99.1
- ALTAltimmune10-QQuarterly report
- ALLOAllogene TherapeuticsSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
- ALLOAllogene Therapeutics8-KCurrent report: material agreement, agreement terminated, results of operations · EX-99.1
- ALLOAllogene Therapeutics10-QQuarterly report
- ACRVAcrivon TherapeuticsReleaseAcrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
- ACRVAcrivon Therapeutics8-KCurrent report: results of operations · EX-99.1
- ACRVAcrivon Therapeutics10-QQuarterly report
- ACETAdicet BioS-8 POSEmployee plan registration (post-effective)
- ACETAdicet Bio8-KCurrent report: results of operations · EX-99.1
- ACETAdicet Bio10-QQuarterly report
Tuesday, May 12109
- ZURAZura BioSCHEDULE 13G/A13G amendment
- ZNTLZentalis Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- ZNTLZentalis Pharmaceuticals10-QQuarterly report
- XFORX4 PharmaceuticalsCORRESPCORRESP
- XFORX4 Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
- VRCAVerrica PharmaceuticalsS-8Employee plan registration
- VRCAVerrica Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- VRCAVerrica Pharmaceuticals10-QQuarterly report
- VNDAVanda PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- UNCYUnicycive Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MAY 12, 2026
- UNCYUnicycive Therapeutics10-QQuarterly report
- TYRATyra BiosciencesSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsS-8Employee plan registration
- TENXTenax Therapeutics8-KCurrent report: results of operations · EX-99.1
- TENXTenax Therapeutics10-QQuarterly report
- SLSSELLAS Life Sciences Group8-KCurrent report: results of operations · EX-99.1
- SLSSELLAS Life Sciences Group10-QQuarterly report
- SLDBSolid Biosciences10-QQuarterly report
- SIONSionna TherapeuticsSCHEDULE 13G/A13G amendment
- SIONSionna Therapeutics8-KCurrent report: results of operations · EX-99.1
- SIONSionna Therapeutics10-QQuarterly report
- SGMTSagimet BiosciencesReleaseSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- SGMTSagimet Biosciences8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- SGMTSagimet Biosciences10-QQuarterly report
- SANASana BiotechnologyReleaseSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
- SABSSAB Biotherapeutics10-QQuarterly report
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
- RXRXRecursion PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- RLMDRelmada Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED MAY 12, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 2025
- RLMDRelmada Therapeutics10-QQuarterly report
- REPLReplimune GroupSCHEDULE 13GPassive >5% holder (13G)
- RAREUltragenyx PharmaceuticalSCHEDULE 13GPassive >5% holder (13G)
- QUREuniQureSCHEDULE 13GPassive >5% holder (13G)
- PYPDPolyPidSCHEDULE 13G/A13G amendment
- PTGXProtagonist TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- PRLDPrelude Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- PRLDPrelude Therapeutics10-QQuarterly report
- PMVPPMV PharmaceuticalsReleasePMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
- PMVPPMV Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- PMVPPMV Pharmaceuticals10-QQuarterly report
- PMNProMIS Neurosciences8-KCurrent report: results of operations · EX-99.1
- PMNProMIS Neurosciences10-QQuarterly report
- PEPGPepGen8-KCurrent report: results of operations · EX-99.1
- PEPGPepGen10-QQuarterly report
- PALIPalisade BioS-3Shelf registration
- PALIPalisade Bio8-KCurrent report: results of operations · EX-99.1
- PALIPalisade Bio10-QQuarterly report
- OVIDOvid TherapeuticsReleaseOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
- OVIDOvid Therapeutics8-KCurrent report · EX-99.1
- OVIDOvid Therapeutics10-QQuarterly report
- ORICOric PharmaceuticalsSCHEDULE 13G/A13G amendment
- OLMAOlema Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- OLMAOlema Pharmaceuticals10-QQuarterly report
- NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
- NKTXNkarta8-KCurrent report: results of operations · EX-99.1
- NKTXNkarta10-QQuarterly report
- NGNENeurogene8-KCurrent report: results of operations · EX-99.1
- NGNENeurogene10-QQuarterly report
- MDNAFMedicenna TherapeuticsReleaseMedicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- MAZEMaze TherapeuticsPOS AMPost-effective amendment
- MAZEMaze Therapeutics8-KCurrent report: results of operations · EX-99.1
- MAZEMaze Therapeutics10-QQuarterly report
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1
- LCTXLineage Cell Therapeutics8-KCurrent report: results of operations · EX-99.1
- LCTXLineage Cell Therapeutics10-QQuarterly report
- LBRXLB Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- LBRXLB Pharmaceuticals424B3Prospectus (resale / update)
- LBRXLB Pharmaceuticals10-QQuarterly report
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
- KYTXKyverna Therapeutics8-KCurrent report: results of operations · EX-99.1
- KYTXKyverna Therapeutics10-QQuarterly report
- KURAKura Oncology8-KCurrent report: results of operations · EX-99.1
- KURAKura Oncology10-QQuarterly report
- JANXJanux TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- IXHLIncannex HealthcareReleaseIncannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
- IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MAY 12, 2026
- IRDOpus Genetics8-KCurrent report: results of operations · EX-99.1
- IRDOpus Genetics10-QQuarterly report
- IMTXImmaticsReleaseImmatics Announces First Quarter 2026 Financial Results and Business Update
- IMTXImmatics6-KForeign issuer report · EX-99.1
- IMNMImmunome8-KCurrent report: results of operations · EX-99.1
- IMNMImmunome10-QQuarterly report
- GUTSFractyl Health8-KCurrent report: results of operations · EX-99.1
- GUTSFractyl Health10-QQuarterly report
- FDMT4D Molecular TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Participate in Upcoming Investor Conferences
- ERASErascaSCHEDULE 13G/A13G amendment
- ENTXEntera BioUPLOADUPLOAD
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- DFTXDefinium Therapeutics8-KCurrent report: other events · EX-99.1
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- CRBUCaribou BiosciencesReleaseCaribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
- COYACoya Therapeutics8-KCurrent report: material agreement
- COYACoya Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- COYACoya Therapeutics424B5Prospectus supplement (offering)
- COYACoya Therapeutics10-QQuarterly report
- CNTBConnect Biopharma8-KCurrent report: results of operations · EX-99.1
- CNTBConnect Biopharma10-QQuarterly report
- CLYMClimb BioReleaseClimb Bio to Present at Upcoming Investor Conferences
- CLNNCleneSCHEDULE 13G/A13G amendment
- CLDXCelldex TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CCCCC4 TherapeuticsReleaseC4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- CCCCC4 Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- CCCCC4 Therapeutics10-QQuarterly report
- CATXPerspective TherapeuticsSCHEDULE 13G/A13G amendment
- CAPRCapricor Therapeutics8-KCurrent report: results of operations · EX-99.1
- BMEABiomea FusionReleaseBiomea Fusion to Participate at Upcoming Investor Conferences
- BEAMBeam TherapeuticsReleaseBeam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
- BCRXBiocryst PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- BBOTBridgeBio Oncology TherapeuticsReleaseBBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
- BBOTBridgeBio Oncology Therapeutics8-KCurrent report: results of operations · EX-99.1
- BBOTBridgeBio Oncology Therapeutics10-QQuarterly report
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ATAIAtai BeckleyReleaseAtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Updatecompany site may be offline after the acquisition; linked to the SEC copy · original
- ATAIAtai Beckley8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- ATAIAtai Beckley10-QQuarterly report
- ARVNArvinasReleaseArvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
- ARVNArvinasReleaseArvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
- ARVNArvinas8-KCurrent report: results of operations · EX-99.1
- ARVNArvinas8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
- ARDXArdelyxSCHEDULE 13GPassive >5% holder (13G)
- ANABAnaptysBioReleaseAnaptys Announces First Quarter 2026 Financial Results and Provides Business Update
- ANABAnaptysBio8-KCurrent report: results of operations · EX-99.1
- ANABAnaptysBio10-QQuarterly report
- ALTAltimmuneSCHEDULE 13GPassive >5% holder (13G)
- AKBAAkebia TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ACRSAclaris TherapeuticsSCHEDULE 13G/A13G amendment
- ACIUAC Immune6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ACHVAchieve Life SciencesS-8Employee plan registration
- ACHVAchieve Life SciencesS-3Shelf registration
- ACHVAchieve Life Sciences8-KCurrent report: results of operations, officer / director change · EX-99.1
- ACHVAchieve Life Sciences10-QQuarterly report
- ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
- ABOSAcumen Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- ABOSAcumen Pharmaceuticals10-QQuarterly report
Monday, May 1178
- XFORX4 PharmaceuticalsUPLOADUPLOAD
- VRDNViridian Therapeutics8-KCurrent report: material agreement, debt / obligation, other events
- TVTXTravere Therapeutics8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1
- TTRXTurn TherapeuticsReleaseTurn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- TTRXTurn Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED MAY 11, 2026
- TTRXTurn Therapeutics10-QQuarterly report
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SGMTSagimet BiosciencesReleaseSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
- SEPNSepterna8-KCurrent report: results of operations · EX-99.1
- SEPNSepterna10-QQuarterly report
- SCYXScynexis10-QQuarterly report
- SANASana BiotechnologyS-8Employee plan registration
- SANASana BiotechnologyReleaseSana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
- SANASana Biotechnology8-KCurrent report: results of operations · EX-99.1
- SANASana Biotechnology10-QQuarterly report
- RVPHReviva PharmaceuticalsReleaseNasdaq CM: RVPH
- OMEROmerosReleaseOmeros Corporation to Announce First Quarter Financial Results on May 13, 2026
- OCSOculis Holding6-KForeign issuer report · EX-99.1
- NTLAIntellia TherapeuticsReleasePresented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUD
- NTLAIntellia Therapeutics8-KCurrent report: results of operations · EX-99.1
- NTLAIntellia Therapeutics10-QQuarterly report
- MLTXMoonLake Immunotherapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- MLTXMoonLake Immunotherapeutics10-QQuarterly report
- MAIAMAIA Biotechnology10-QQuarterly report
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlightscompany site may be offline after the acquisition; linked to the SEC copy · original
- LXEOLexeo Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- LXEOLexeo Therapeutics10-QQuarterly report
- LQDALiquidia8-KCurrent report: results of operations, other events · EX-99.1 EXHIBIT 99.1
- LQDALiquidia10-QQuarterly report
- LENZLENZ Therapeutics8-KCurrent report: results of operations · EX-99.1
- LENZLENZ Therapeutics10-QQuarterly report
- KAPAKairos PharmaPRE 14APRE 14A
- INBXInhibrx Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- HROWHarrowSCHEDULE 13G/A13G amendment
- HROWHarrow8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- HROWHarrow10-QQuarterly report
- GUTSFractyl Health8-KCurrent report: Reg FD disclosure · EX-99.1
- GANXGain TherapeuticsReleaseGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
- GANXGain Therapeutics8-KCurrent report: results of operations · EX-99.1
- GANXGain Therapeutics10-QQuarterly report
- FDMT4D Molecular TherapeuticsCORRESPCORRESP
- FBRXForte BiosciencesReleaseForte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Updatecompany site may be offline after the acquisition
- FBRXForte Biosciences10-QQuarterly report
- ERASErasca8-KCurrent report: results of operations · EX-99.1
- ERASErasca10-QQuarterly report
- ENTAEnanta Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- ELTXElicio Therapeutics8-KCurrent report: results of operations · EX-99.1
- ELTXElicio Therapeutics10-QQuarterly report
- ELDNEledon PharmaceuticalsEFFECTRegistration effective
- EIKNEikon Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- EIKNEikon Therapeutics10-QQuarterly report
- DYNDyne TherapeuticsReleaseDyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- DYNDyne TherapeuticsReleaseDyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Mu
- DYNDyne Therapeutics8-KCurrent report: results of operations · EX-99.1
- DYNDyne Therapeutics10-QQuarterly report
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 COMPANY PRESENTATION
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE TITLED "ALPHA TAU ANNOUNCES GROUNDBREAKING INTERIM RESULTS FROM IT
- DBVTDBV TechnologiesDEF 14AProxy statement
- DBVTDBV TechnologiesARSAnnual report to shareholders
- CYDYCytoDynDForm D (exempt offering)
- CUECue BiopharmaPRE 14APRE 14A
- CRVOCervoMedSCHEDULE 13G/A13G amendment
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CLRBCellectar BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- CHRSCoherus OncologySCHEDULE 13G/A13G amendment
- CHRSCoherus Oncology8-KCurrent report: results of operations · EX-99.1
- CHRSCoherus Oncology10-QQuarterly report
- CGONCG OncologyReleaseCG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
- CATXPerspective TherapeuticsReleasePerspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
- CATXPerspective Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- CATXPerspective Therapeutics10-QQuarterly report
- BMEABiomea FusionReleaseBiomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
- BMEABiomea Fusion8-KCurrent report: results of operations · EX-99.1
- BMEABiomea Fusion10-QQuarterly report
- BCAXBicara Therapeutics8-KCurrent report: results of operations · EX-99.1
- BCAXBicara Therapeutics10-QQuarterly report
- ATHEAlterity TherapeuticsReleaseAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ARVNArvinas10-QQuarterly report
- APGEApogee Therapeutics8-KCurrent report: results of operations · EX-99.1
- APGEApogee Therapeutics10-QQuarterly report
- ANTXAN2 Therapeutics8-KCurrent report: results of operations · EX-99.1
- ANTXAN2 Therapeutics10-QQuarterly report
- ANABAnaptysBioReleaseAnaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
- ANABAnaptysBio8-KCurrent report: officer / director change
- AKTSAktis Oncology8-KCurrent report: results of operations · EX-99.1
- AKTSAktis Oncology10-QQuarterly report
- ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR ORAL ELRAGLUSIB AND STRATEGIC INITIATIVES TO ADVANCE THE ELRAGLUSIB DEVELOPMENT PROGRAM
- ACTUActuate Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE
- ABVXAbivaxSCHEDULE 13D/A13D amendment
Friday, May 834
- VRDNViridian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- VRDNViridian Therapeutics424B5Prospectus supplement (offering)
- VRDNViridian Therapeutics424B5Prospectus supplement (offering)
- TNGXTango Therapeutics8-KCurrent report: officer / director change
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- SCYXScynexisEFFECTRegistration effective
- SCYXScynexis424B3Prospectus (resale / update)
- RNTXRein TherapeuticsSCHEDULE 13G/A13G amendment
- RNTXRein TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- OCGNOcugen10-QQuarterly report
- NKTRNektar Therapeutics8-KCurrent report: material agreement, officer / director change
- NKTRNektar Therapeutics424B5Prospectus supplement (offering)
- NKTRNektar Therapeutics10-QQuarterly report
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- LGVNLongeveron8-KCurrent report: other events · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON MAY 8, 2026
- KPRXKiora PharmaceuticalsReleaseKiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- KPRXKiora Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- KPRXKiora Pharmaceuticals10-QQuarterly report
- IMCRImmunocoreS-8Employee plan registration
- GERNGeronSCHEDULE 13G/A13G amendment
- FDMT4D Molecular TherapeuticsUPLOADUPLOAD
- ENTXEntera BioS-3Shelf registration
- ENTXEntera Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- ENTXEntera Bio10-QQuarterly report
- ELOXEloxx PharmaceuticalsDEF 14CDEF 14C
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MAY 8, 2026
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MAY 8, 2026
- CLRBCellectar Biosciences8-KCurrent report: material agreement, unregistered sale of equity, other events
- CGTXCognition Therapeutics10-QQuarterly report
- CGONCG OncologyReleaseCG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
- CGONCG Oncology8-KCurrent report: results of operations · EX-99.1
- CGONCG Oncology10-QQuarterly report
- BIOABioAge Labs8-KCurrent report: results of operations · EX-99.1
- BIOABioAge Labs10-QQuarterly report
- BCAXBicara TherapeuticsSCHEDULE 13G/A13G amendment
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- ARTVArtiva BiotherapeuticsReleaseArtiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- ARTVArtiva BiotherapeuticsReleaseArtiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
- ARTVArtiva BiotherapeuticsFWPFree writing prospectus (offering terms)
- ARTVArtiva Biotherapeutics8-KCurrent report: other events
- ARTVArtiva Biotherapeutics8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1
- ARTVArtiva Biotherapeutics424B5Prospectus supplement (offering)
- ARTVArtiva Biotherapeutics10-QQuarterly report
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Thursday, May 7141
- ZYMEZymeworks8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- ZYMEZymeworks10-QQuarterly report
- ZURAZura Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- ZURAZura Bio10-QQuarterly report
- XERSXeris Biopharma8-KCurrent report: results of operations · EX-99.1
- XERSXeris Biopharma10-QQuarterly report
- XENEXenon Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- XENEXenon Pharmaceuticals10-QQuarterly report
- WVEWave Life SciencesDEF 14AProxy statement
- VYGRVoyager TherapeuticsReleaseVoyager Reports First Quarter 2026 Financial and Operating Results
- VYGRVoyager Therapeutics8-KCurrent report: results of operations · EX-99.1
- VYGRVoyager Therapeutics10-QQuarterly report
- VTVTvTv TherapeuticsReleasevTv Therapeutics to Participate in Upcoming May Investor Conferences
- VSTMVerastem8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- VSTMVerastem10-QQuarterly report
- VRDNViridian TherapeuticsFWPFree writing prospectus (offering terms)
- VRDNViridian TherapeuticsFWPFree writing prospectus (offering terms)
- VRDNViridian Therapeutics305B2305B2
- VNDAVanda Pharmaceuticals10-QQuarterly report
- VIRVir Biotechnology10-QQuarterly report
- VERAVera TherapeuticsReleaseVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
- VERAVera Therapeutics8-KCurrent report: results of operations · EX-99.1
- VERAVera Therapeutics10-QQuarterly report
- TVTXTravere TherapeuticsReleaseTravere Therapeutics to Participate at Upcoming Investor Conferences
- TVTXTravere TherapeuticsFWPFree writing prospectus (offering terms)
- TVTXTravere Therapeutics424B5Prospectus supplement (offering)
- TVTXTravere Therapeutics305B2305B2
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TECXTectonic Therapeutic8-KCurrent report: results of operations · EX-99.1
- TECXTectonic Therapeutic10-QQuarterly report
- STOKStoke Therapeutics8-KCurrent report: results of operations · EX-99.1
- STOKStoke Therapeutics10-QQuarterly report
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- RVPHReviva PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- RNTXRein TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- REPLReplimune GroupSCHEDULE 13G/A13G amendment
- RCKTRocket PharmaceuticalsReleaseRocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
- RCKTRocket Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- RCKTRocket Pharmaceuticals10-QQuarterly report
- RAPPRapport Therapeutics8-KCurrent report: results of operations · EX-99.1
- RAPPRapport Therapeutics10-QQuarterly report
- QNRXQuoin Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- QNRXQuoin Pharmaceuticals10-QQuarterly report
- PMNProMIS NeurosciencesSCHEDULE 13G/A13G amendment
- PHIOPhio Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- PHIOPhio Pharmaceuticals10-QQuarterly report
- PCSAProcessa Pharmaceuticals10-QQuarterly report
- OTLKOutlook TherapeuticsDForm D (exempt offering)
- OCGNOcugen8-KCurrent report: material agreement, agreement terminated, results of operations
- NRXPNRX PharmaceuticalsReleasePreliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospita
- NKTRNektar Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2026 RESULTS."
- NGENNervGen PharmaS-8Employee plan registration
- NAMSNewAmsterdam Pharma8-KCurrent report: results of operations · EX-99.1
- NAMSNewAmsterdam Pharma10-QQuarterly report
- KODKodiak SciencesReleaseKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
- KODKodiak Sciences8-KCurrent report: results of operations · EX-99.1
- KODKodiak Sciences10-QQuarterly report
- JBIOJade BiosciencesS-8Employee plan registration
- JBIOJade BiosciencesS-3Shelf registration
- JBIOJade BiosciencesS-3Shelf registration
- JBIOJade Biosciences8-KCurrent report: results of operations · EX-99.1
- JBIOJade Biosciences424B3Prospectus (resale / update)
- JBIOJade Biosciences424B3Prospectus (resale / update)
- JBIOJade Biosciences10-QQuarterly report
- JANXJanux TherapeuticsReleaseJanux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
- JANXJanux Therapeutics8-KCurrent report: results of operations · EX-99.1
- JANXJanux Therapeutics10-QQuarterly report
- INSMInsmed8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- INSMInsmed10-QQuarterly report
- INMBInmune Bio10-QQuarterly report
- INABIN8bioS-8 POSEmployee plan registration (post-effective)
- INABIN8bioS-8 POSEmployee plan registration (post-effective)
- INABIN8bioS-8 POSEmployee plan registration (post-effective)
- INABIN8bioS-8 POSEmployee plan registration (post-effective)
- INABIN8bioS-8 POSEmployee plan registration (post-effective)
- INABIN8bioS-8Employee plan registration
- INABIN8bio8-KCurrent report: results of operations, officer / director change, shareholder vote · EX-99.1
- INABIN8bio10-QQuarterly report
- IMMXImmix Biopharma10-QQuarterly report
- IBRXImmunityBio8-KCurrent report: results of operations · EX-99.1
- IBRXImmunityBio10-QQuarterly report
- HRMYHarmony Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- HRMYHarmony Biosciences10-QQuarterly report
- GPCRStructure Therapeutics8-KCurrent report: material agreement, results of operations, other events · EX-99.1 EXHIBIT 99.1
- GPCRStructure Therapeutics424B5Prospectus supplement (offering)
- GPCRStructure Therapeutics10-QQuarterly report
- GNLXGenelux10-QQuarterly report
- GLUEMonte Rosa Therapeutics8-KCurrent report: results of operations · EX-99.1
- GLUEMonte Rosa Therapeutics10-QQuarterly report
- FHTXFoghorn Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- FHTXFoghorn Therapeutics10-QQuarterly report
- FDMT4D Molecular TherapeuticsS-3Shelf registration
- FDMT4D Molecular Therapeutics8-KCurrent report: results of operations · EX-99.1
- FDMT4D Molecular Therapeutics10-QQuarterly report
- EYPTEyePoint10-QQuarterly report
- EWTXEdgewise TherapeuticsS-8Employee plan registration
- EWTXEdgewise Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- EWTXEdgewise Therapeutics10-QQuarterly report
- EVMNEvommune8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- EVMNEvommune424B3Prospectus (resale / update)
- EVMNEvommune10-QQuarterly report
- ELVNEnliven Therapeutics8-KCurrent report: results of operations · EX-99.1
- ELVNEnliven Therapeutics10-QQuarterly report
- ELOXEloxx PharmaceuticalsS-1Registration statement
- ELDNEledon PharmaceuticalsUPLOADUPLOAD
- ELDNEledon PharmaceuticalsCORRESPCORRESP
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MAY 7, 2026
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- DFTXDefinium Therapeutics8-KCurrent report: results of operations · EX-99.1
- DFTXDefinium Therapeutics10-QQuarterly report
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
- CTMXCytomX Therapeutics8-KCurrent report: results of operations · EX-99.1
- CTMXCytomX Therapeutics10-QQuarterly report
- CRVSCorvus PharmaceuticalsS-8Employee plan registration
- CRVSCorvus Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- CRVSCorvus Pharmaceuticals10-QQuarterly report
- CRNXCrinetics PharmaceuticalsReleaseCrinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Updatecompany site may be offline after the acquisition; linked to the SEC copy · original
- CRNXCrinetics Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- CRNXCrinetics Pharmaceuticals10-QQuarterly report
- CRDLCardiol TherapeuticsReleaseCardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED MAY 7, 2026
- CRBUCaribou BiosciencesReleaseCaribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
- CRBUCaribou Biosciences8-KCurrent report: results of operations · EX-99.1
- CRBUCaribou Biosciences10-QQuarterly report
- CLYMClimb BioReleaseClimb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
- CLYMClimb Bio8-KCurrent report: results of operations · EX-99.1
- CLYMClimb Bio10-QQuarterly report
- CLDXCelldex TherapeuticsReleaseCelldex Reports First Quarter Financial Results and Provides Corporate Update
- CLDXCelldex Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- CLDXCelldex Therapeutics10-QQuarterly report
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
- CGTXCognition Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
- CGEMCullinan Therapeutics8-KCurrent report: results of operations · EX-99.1
- CGEMCullinan Therapeutics10-QQuarterly report
- CAPRCapricor Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- BEAMBeam TherapeuticsReleaseBeam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
- BEAMBeam Therapeutics8-KCurrent report: results of operations · EX-99.1
- BEAMBeam Therapeutics10-QQuarterly report
- BDTXBlack Diamond Therapeutics8-KCurrent report: results of operations · EX-99.1
- BDTXBlack Diamond Therapeutics10-QQuarterly report
- ATHEAlterity TherapeuticsReleaseAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- ANNXAnnexonReleaseAnnexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
- ANNXAnnexon8-KCurrent report: results of operations · EX-99.1
- ANNXAnnexon10-QQuarterly report
- AMLXAmylyx Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- AMLXAmylyx Pharmaceuticals10-QQuarterly report
- ALDXAldeyra Therapeutics10-QQuarterly report
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
- AKBAAkebia Therapeutics8-KCurrent report: results of operations · EX-99.1
- AKBAAkebia Therapeutics10-QQuarterly report
- ADAGAdageneSCHEDULE 13GPassive >5% holder (13G)
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- ACRSAclaris Therapeutics8-KCurrent report: results of operations · EX-99.1
- ACRSAclaris Therapeutics10-QQuarterly report
- ACHVAchieve Life SciencesSCHEDULE 13G/A13G amendment
- ABVXAbivax6-KForeign issuer report · EX-99.1
- ABVXAbivax424B7Prospectus supplement
- ABSIAbsci8-KCurrent report: results of operations, other events · EX-99.1
- ABSIAbsci10-QQuarterly report
- ABOSAcumen PharmaceuticalsReleaseAcumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
- AARDAardvark Therapeutics8-KCurrent report: results of operations · EX-99.1
- AARDAardvark Therapeutics10-QQuarterly report
Wednesday, May 649
- ZURAZura BioSCHEDULE 13G/A13G amendment
- XNCRXencor8-KCurrent report: results of operations · EX-99.1
- XNCRXencor10-QQuarterly report
- XFORX4 PharmaceuticalsS-3Shelf registration
- XFORX4 Pharmaceuticals10-QQuarterly report
- WVEWave Life SciencesSCHEDULE 13G/A13G amendment
- VRDNViridian Therapeutics424B5Prospectus supplement (offering)
- VRDNViridian Therapeutics424B5Prospectus supplement (offering)
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VORVor BiopharmaEFFECTRegistration effective
- VNDAVanda Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- VIRVir Biotechnology8-KCurrent report: results of operations · EX-99.1
- UNCYUnicycive TherapeuticsS-8Employee plan registration
- TSHATaysha Gene Therapies8-KCurrent report: results of operations · EX-99.1
- TSHATaysha Gene Therapies10-QQuarterly report
- TNGXTango TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TGTXTg Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- TGTXTg Therapeutics10-QQuarterly report
- SRPTSarepta TherapeuticsReleaseSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
- SRPTSarepta Therapeutics8-KCurrent report: results of operations · EX-99.1
- SRPTSarepta Therapeutics10-QQuarterly report
- SCYXScynexisUPLOADUPLOAD
- SCYXScynexisCORRESPCORRESP
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
- RXRXRecursion Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- RXRXRecursion Pharmaceuticals10-QQuarterly report
- RVMDRevolution Medicines8-KCurrent report: results of operations · EX-99.1
- RVMDRevolution Medicines10-QQuarterly report
- RNTXRein TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- RNACCartesian TherapeuticsSCHEDULE 13G/A13G amendment
- RAREUltragenyx PharmaceuticalReleaseUltragenyx to Participate at Bank of America’s 2026 Healthcare Conference
- RAREUltragenyx Pharmaceutical10-QQuarterly report
- QUREuniQureSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13D/A13D amendment
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- PCVXVaxcyte8-KCurrent report: results of operations · EX-99.1
- PCVXVaxcyte10-QQuarterly report
- NRIXNurix TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- NKTRNektar TherapeuticsSCHEDULE 13G/A13G amendment
- NAMSNewAmsterdam PharmaSCHEDULE 13G/A13G amendment
- NAMSNewAmsterdam PharmaDEF 14AProxy statement
- NAMSNewAmsterdam PharmaARSAnnual report to shareholders
- MLYSMineralys Therapeutics8-KCurrent report: results of operations · EX-99.1
- MLYSMineralys Therapeutics10-QQuarterly report
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
- KYMRKymera TherapeuticsSCHEDULE 13G/A13G amendment
- KYMRKymera TherapeuticsReleaseWATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
- JANXJanux TherapeuticsSCHEDULE 13G/A13G amendment
- INSMInsmedSCHEDULE 13GPassive >5% holder (13G)
- IMUXImmunicSCHEDULE 13GPassive >5% holder (13G)
- IMCRImmunocore8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- IMCRImmunocore10-QQuarterly report
- GERNGeron10-QQuarterly report
- FHTXFoghorn TherapeuticsSCHEDULE 13G/A13G amendment
- FBIOFortress BiotechReleaseJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
- EYPTEyePoint8-KCurrent report: results of operations · EX-99.1
- EIKNEikon TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- DYNDyne TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CMPSCOMPASS PathwaysReleaseCompass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
- CMMBChemomab Therapeutics6-KForeign issuer report
- CLRBCellectar Biosciences424B5Prospectus supplement (offering)
- CLDXCelldex TherapeuticsSCHEDULE 13G/A13G amendment
- BCRXBiocryst Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE
- BCRXBiocryst Pharmaceuticals10-QQuarterly report
- BCAXBicara TherapeuticsSCHEDULE 13G/A13G amendment
- BBOTBridgeBio Oncology Therapeutics424B3Prospectus (resale / update)
- APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1
- ALTAltimmuneReleaseAltimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
- AGMBAgomab TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- AGIOAgios PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- ADMAAdma Biologics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- ADMAAdma Biologics10-QQuarterly report
- ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS ANNOUNCES KEY APPOINTMENT OF INDUSTRY VETERAN TO BOARD OF DIRECTORS
- ACTUActuate TherapeuticsDEFA14AProxy soliciting material
- ACTUActuate Therapeutics8-KCurrent report: officer / director change, other events · EX-99.1 PRESS RELEASE
Tuesday, May 566
- ZNTLZentalis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- ZBIOZenas BioPharmaSCHEDULE 13DActivist / >5% holder (13D)
- XNCRXencor8-KCurrent report: Reg FD disclosure · EX-99.1
- WVEWave Life SciencesUPLOADUPLOAD
- VRDNViridian TherapeuticsFWPFree writing prospectus (offering terms)
- VRDNViridian Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
- VRDNViridian Therapeutics8-KCurrent report: results of operations · EX-99.1
- VRDNViridian Therapeutics10-QQuarterly report
- VNDAVanda PharmaceuticalsEFFECTRegistration effective
- VKTXViking TherapeuticsReleaseE-mail Alerts
- TVTXTravere Therapeutics424B5Prospectus supplement (offering)
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SYRESpyre Therapeutics8-KCurrent report: results of operations · EX-99.1
- SYRESpyre Therapeutics10-QQuarterly report
- SLDBSolid BiosciencesSCHEDULE 13G/A13G amendment
- SANASana BiotechnologyReleaseSana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
- RYTMRhythm PharmaceuticalsS-8Employee plan registration
- RYTMRhythm PharmaceuticalsDEFA14AProxy soliciting material
- RYTMRhythm Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- RYTMRhythm Pharmaceuticals10-QQuarterly report
- RLAYRelay Therapeutics8-KCurrent report: results of operations · EX-99.1
- RLAYRelay Therapeutics10-QQuarterly report
- RCUSArcus BiosciencesReleaseArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pi...
- RCUSArcus Biosciences8-KCurrent report: results of operations · EX-99.1
- RCUSArcus Biosciences10-QQuarterly report
- RAREUltragenyx Pharmaceutical8-KCurrent report: results of operations · EX-99.1
- QUREuniQure8-KCurrent report: results of operations · EX-99.1
- QUREuniQure10-QQuarterly report
- QTTBQ32 Bio8-KCurrent report: results of operations · EX-99.1
- QTTBQ32 Bio10-QQuarterly report
- PTGXProtagonist Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- PTGXProtagonist Therapeutics10-QQuarterly report
- OKUROnKure Therapeutics8-KCurrent report: results of operations · EX-99.1
- OKUROnKure Therapeutics10-QQuarterly report
- OCGNOcugen8-KCurrent report: results of operations, other events · EX-99.1 EXHIBIT 99.1
- NVCTNuvectis Pharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- NVCTNuvectis Pharma10-QQuarterly report
- NTLAIntellia TherapeuticsReleaseCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
- LGVNLongeveronPRE 14APRE 14A
- IRONDisc Medicine8-KCurrent report: results of operations · EX-99.1
- IRONDisc Medicine10-QQuarterly report
- INMBInmune Bio8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MAY 5, 2026
- IDYAIDEAYA BiosciencesS-3ASRAutomatic shelf registration
- IDYAIDEAYA Biosciences8-KCurrent report: other events
- IDYAIDEAYA Biosciences8-KCurrent report: results of operations · EX-99.1
- IDYAIDEAYA Biosciences424B5Prospectus supplement (offering)
- IDYAIDEAYA Biosciences10-QQuarterly report
- EXELExelixisReleaseExelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
- EXELExelixis8-KCurrent report: results of operations, other events · EX-99.1
- EXELExelixis10-QQuarterly report
- ELOXEloxx Pharmaceuticals10-QQuarterly report
- DTILPrecision Biosciences8-KCurrent report: results of operations · EX-99.1
- DTILPrecision Biosciences10-QQuarterly report
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MAY 5, 2026
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- DBVTDBV Technologies8-KCurrent report: officer / director change
- CTNMContineum Therapeutics8-KCurrent report: results of operations · EX-99.1
- CTNMContineum Therapeutics10-QQuarterly report
- COGTCogent BiosciencesRelease- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation
- COGTCogent Biosciences8-KCurrent report: results of operations · EX-99.1
- COGTCogent Biosciences10-QQuarterly report
- CMPXCompass Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- CMPXCompass Therapeutics10-QQuarterly report
- CLYMClimb Bio8-KCurrent report: Reg FD disclosure · EX-99.1
- CLNNCleneReleaseClene to Present at Upcoming May Conferences
- CLNNCleneReleaseClene Announces $7 Million Underwritten Offering of Common Stock
- CLNNClene8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- CLNNClene424B5Prospectus supplement (offering)
- CLNNClene424B5Prospectus supplement (offering)
- CHRSCoherus OncologyDEFA14AProxy soliciting material
- BMEABiomea FusionReleaseBiomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
- AUTLAutolus TherapeuticsEFFECTRegistration effective
- AUTLAutolus TherapeuticsEFFECTRegistration effective
- ARVNArvinasReleaseArvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Monday, May 431
- VORVor BiopharmaCORRESPCORRESP
- TVTXTravere Therapeutics8-KCurrent report: results of operations · EX-99.1
- TVTXTravere Therapeutics10-QQuarterly report
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB Biotherapeutics8-KCurrent report: material agreement
- RNTXRein Therapeutics8-KCurrent report: material agreement, other events · EX-99.1
- RNTXRein Therapeutics424B5Prospectus supplement (offering)
- RLMDRelmada TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- PYPDPolyPidSCHEDULE 13G/A13G amendment
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- PMVPPMV PharmaceuticalsSCHEDULE 13G/A13G amendment
- ORKAOruka TherapeuticsSCHEDULE 13D/A13D amendment
- ORICOric Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- ORICOric Pharmaceuticals10-QQuarterly report
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- OKUROnKure TherapeuticsEFFECTRegistration effective
- OCGNOcugen8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- MRKRMarker Therapeutics8-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
- KYTXKyverna Therapeutics8-KCurrent report: other events · EX-99.1
- KTTAPasithea Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED MAY 4, 2026
- IMUXImmunicEFFECTRegistration effective
- IMMXImmix BiopharmaSCHEDULE 13G/A13G amendment
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MAY 4, 2026.
- DBVTDBV TechnologiesS-8Employee plan registration
- CLYMClimb BioDForm D (exempt offering)
- CLNNClene8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- CATXPerspective Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- CABACabaletta BioReleaseCabaletta Bio Announces Pricing of $150 Million Underwritten Offering
- CABACabaletta Bio8-KCurrent report: material agreement, results of operations, other events · EX-99.1
- CABACabaletta Bio8-KCurrent report: other events
- CABACabaletta Bio424B5Prospectus supplement (offering)
- BCYCBicycle TherapeuticsSCHEDULE 13G/A13G amendment
- BCRXBiocryst Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE
- BBOTBridgeBio Oncology TherapeuticsEFFECTRegistration effective
- AXSMAxsome Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
- AXSMAxsome Therapeutics10-QQuarterly report
- ANABAnaptysBioReleaseAnaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
- ADMAAdma Biologics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- ADCTADC Therapeutics8-KCurrent report: results of operations · EX-99.1
- ADCTADC Therapeutics10-QQuarterly report
Friday, May 19
- WVEWave Life SciencesPRER14APRER14A
- WVEWave Life SciencesCORRESPCORRESP
- VORVor BiopharmaUPLOADUPLOAD
- TLSATiziana Life Sciences20-FAnnual report (foreign)
- STROSutro BiopharmaSCHEDULE 13GPassive >5% holder (13G)
- SCYXScynexisS-3Shelf registration
- SABSSAB BiotherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- OLMAOlema Pharmaceuticals8-KCurrent report: material agreement, debt / obligation
- KPRXKiora PharmaceuticalsARSAnnual report to shareholders
- IMUXImmunicCORRESPCORRESP
- ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE HEMANGEOL LAUNCH
- ELOXEloxx PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- ELOXEloxx Pharmaceuticals8-KCurrent report: shareholder vote
- ELDNEledon PharmaceuticalsS-3Shelf registration
- DRTSAlpha Tau MedicalEFFECTRegistration effective
- DBVTDBV TechnologiesPRE 14APRE 14A
- CUECue BiopharmaS-8Employee plan registration
- CUECue Biopharma8-KCurrent report: material agreement, unregistered sale of equity, officer / director change · EX-99.1
- CRBUCaribou BiosciencesDEFR14ADEFR14A
- AUTLAutolus TherapeuticsCORRESPCORRESP
- AUTLAutolus TherapeuticsCORRESPCORRESP
- ARVNArvinas8-KCurrent report: Reg FD disclosure, other events · EX-99.1
- ALTAltimmuneSCHEDULE 13GPassive >5% holder (13G)
- ALTAltimmuneSCHEDULE 13GPassive >5% holder (13G)
- ALTAltimmuneSCHEDULE 13GPassive >5% holder (13G)
- ALDXAldeyra Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1